Loading...
Teva Pharmaceutical Industries Community
NYSE:TEVA Community- 1 Narratives written by author
- 2 Comments on narratives written by author
- 94 Fair Values set on narratives written by author
Community Investing Ideas
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
Key Takeaways Teva's diversified portfolio and expanding branded and biosimilar products are expected to drive steady, higher-margin growth and profitability amid demographic and regulatory tailwinds. Operational efficiencies, modernization, and a resilient generics platform are strengthening Teva's financial foundation, supporting income growth, free cash flow, and debt reduction.Read more
1users have liked this narrative
2users have commented on this narrative
44users have followed this narrative
AN
US$27.45
7.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
2.77% p.a.
Profit Margin
8.15%
Future PE
28.16x
Share price in 2028
US$35.08